Pfizer Inc details 61% tilrekimig Phase 2 response
Pfizer reported Phase 2 results for tilrekimig in atopic dermatitis, with a 61% EASI-75 response rate at a monthly 200 mg dose, compared to 9.1% on placebo. The study is ongoing, with Phase 3 trials initiated. Pfizer shares closed at $28.52 on Sept. 30, before the detailed data release.
How this was made
The 30-second read
Why it matters
The Phase 2 readout provides the first quantitative efficacy signal, setting expectations for upcoming Phase 3 trials that will include an active comparator.
Market read
New trial data can move Pfizer's stock and influence valuation of competing dermatology biologics.
What to watch
Safety profile shows comparable adverse events to placebo, which could temper enthusiasm.
Background
Pfizer's tilrekimig targets IL‑4, IL‑13 and TSLP for atopic dermatitis, adding to its pipeline of inflammatory disease candidates.
Ticker impact
Pfizer disclosed Phase 2 atopic dermatitis trial results showing 61% EASI-75 response for the monthly tilrekimig dose, a new primary disclosure.
potential modest upside as market prices in the encouraging response rates
The trial shows statistically significant improvement versus placebo, but no head‑to‑head comparison with an approved therapy, limiting upside.
Market effects
Strengthens the broader dermatology/biologics sector, may prompt re‑rating of peers like Sanofi and J&J.
U.S. biotech market could see slight uplift on the day of release.
Limited to investors focused on biotech and pharma pipelines.
Counterpoint
Without a direct dupilumab comparator, the data may be over‑hyped; investors could remain cautious.
Key entities
- CompanyPfizer Inc.
U.S. pharmaceutical giant reporting the trial data.
- DrugTilrekimig
Investigational antibody for atopic dermatitis.
